According to filings with the U.S. Securities and Exchange Commission, Cx Precision Medicine is raising up to $4,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Danguole Altman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cx Precision Medicine
Cx Precision Medicine is a life science company developing blood-based biomarker screening technology as well as companion diagnostics for therapeutic agents. Our lead products are focused on neurodegenerative diseases such as Alzheimers disease, Parkinsons disease, and other dementia-causing disorders. Our low-cost and non-invasive tests will rule out Alzheimers disease and Parkinsons disease for many and help identify others who will benefit from more comprehensive testing. Our test will also help physicians treat patients with the right medicines more quickly.

To learn more about Cx Precision Medicine, visit http://cxpmed.com/
Company Linkedin Page: https://www.linkedin.com/company/cx-precision-medicine-inc./

Contact:
Danguole Altman, President and Chief Executive Officer
817-523-1301
https://www.linkedin.com/in/danguolealtman/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.